Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato
Utgiver(e) Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av sarkom
  • Engelsk tittel -
  • Versjon - 3
  • Status - Publisert
  • IS-nr - 2697
  • ISBN - 978-82-8081-518-7
  • DOI -
  • Revisjonsdato - 10.04.2018
  • Neste revisjon -
  • Publikasjonsdato -
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer
 
  1. Trovik C, Bauer HCF, Styring E, Sundby Hall K, Vult Von Steyern F, Eriksson S, et al. The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma. Acta Orthop 2017;88(3):341–7.
  2. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005;103(4):821–9.
  3. Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ, et al. Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncol 2015;54(1):25–33.
  4. Zaikova O, Sundby Hall K, Styring E, Eriksson M, Trovik CS, Bergh P, et al. Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia--SSG Central Register 25 years’ experience. J Surg Oncol 2015;112(8):853–60.
  5. Gold DG, Neglia JP, Dusenbery KE. Second neoplasms after megavoltage radiation for pediatric tumors. Cancer 2003;97(10):2588–96.
  6. Elliott P, Kleinschmidt I. Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. Occup Environ Med 1997;54(1):14–8.
  7. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85(14):1121–8.
  8. Kinge B, Tranheim RS, Eide NA. Retinoblastom--arvelig øyekreft hos barn. Tidsskr Nor Lægeforen 2004;124(2):183–5.
  9. Smith LM, Donaldson SS. Incidence and management of secondary malignancies in patients with retinoblastoma and Ewing’s sarcoma. Oncology (Williston Park) 1991;5(5):135–41; discussion 42.
  10. Moppett J, Oakhill A, Duncan AW. Second malignancies in children: the usual suspects? Eur J Radiol 2001;38(3):235–48.
  11. Andreassen A, Øyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993;53(3):468–71.
  12. Hung J, Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl 1997;273: 68–73.
  13. Li FP, Fraumeni JF, Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71(4):747–52.
  14. Thoresen SO. Li-Fraumeni-syndromet og p53-genet. Tidsskr Nor Lægeforen 1992;112(7):887–9.
  15. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326(20):1301–8.
  16. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98(1):15–25.
  17. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000;120(2):91–8.
  18. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992;326(20):1309–15.
  19. Zhou H, Coffin CM, Perkins SL, Tripp SR, Liew M, Viskochil DH. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol 2003;27(10):1337–45.
  20. Weiss SW, Enzinger FM, Goldblum JR. Enzinger and Weiss’s soft tissue tumors. 4. utg. St. Louis: Mosby; 2001.
  21. Haibach H, Farrell C, Dittrich FJ. Neoplasms arising in Paget’s disease of bone: a study of 82 cases. Am J Clin Pathol 1985;83(5):594–600.
  22. Huvos AG, Butler A, Bretsky SS. Osteogenic sarcoma associated with Paget’s disease of bone. A clinicopathologic study of 65 patients. Cancer 1983;52(8):1489–95.
  23. Liu J, Hudkins PG, Swee RG, Unni KK. Bone sarcomas associated with Ollier’s disease. Cancer 1987;59(7):1376–85.
  24. Schwartz HS, Zimmerman NB, Simon MA, Wroble RR, Millar EA, Bonfiglio M. The malignant potential of enchondromatosis. J Bone Joint Surg Am 1987;69(2):269–74.
  25. Wick MR, Siegal GP, Unni KK, McLeod RA, Greditzer HG, III. Sarcomas of bone complicating osteitis deformans (Paget’s disease): fifty years’ experience. Am J Surg Pathol 1981;5(1):47–59.
  26. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88(2):398–406.
  27. Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002;52(5):1231–7.
  28. Murray EM, Werner D, Greeff EA, Taylor DA. Postradiation sarcomas: 20 cases and a literature review. Int J Radiat Oncol Biol Phys 1999;45(4):951–61.
  29. Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller T, Shah IC. Radiation-induced sarcoma of bone. Cancer 1971;28(5):1087–99.
  30. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer 1998;82(1):8–34.
  31. Hawkins MM, Wilson LM, Burton HS, Potok MH, Winter DL, Marsden HB, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996;88(5):270–8.
  32. Menu-Branthomme A, Rubino C, Shamsaldin A, Hawkins MM, Grimaud E, Dondon MG, et al. Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. Int J Cancer 2004;110(1):87–93.
  33. Bjerkehagen B, Smeland S, Walberg L, Skjeldal S, Hall KS, Nesland JM, et al. Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital. Acta Oncol 2008;47(8):1475–82.
  34. Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH. Radiation-induced breast sarcoma. Am J Surg 2002;184(4):356–8.
  35. Cha C, Antonescu CR, Quan ML, Maru S, Brennan MF. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004;239(6):903–9.
  36. Lagrange JL, Ramaioli A, Chateau MC, Marchal C, Resbeut M, Richaud P, et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Federation Nationale des Centres de Lutte Contre le Cancer. Radiology 2000;216(1):197–205.
  37. Souba WW, McKenna RJ, Jr., Meis J, Benjamin R, Raymond AK, Mountain CF. Radiation-induced sarcomas of the chest wall. Cancer 1986;57(3):610–5.
  38. Huvos AG, Sundaresan N, Bretsky SS, Butler A. Osteogenic sarcoma of the skull. A clinicopathologic study of 19 patients. Cancer 1985;56(5):1214–21.
  39. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 2016;6:20.
  40. Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand 2001;72(2):150–9.
  41. Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994;65(1):47–50.
  42. Rydholm A. Improving the management of soft tissue sarcoma. Diagnosis and treatment should be given in specialist centres. BMJ 1998;317(7151):93–4.
  43. Bhangu AA, Beard JA, Grimer RJ. Should soft tissue sarcomas be treated at a specialist centre? Sarcoma 2004;8(1):1–6.
  44. Kransdorf MJ, Murphey MD. Radiologic evaluation of soft-tissue masses: a current perspective. AJR Am J Roentgenol 2000;175(3):575–87.
  45. Kransdorf MJ, Murphey MD. Imaging of soft tissue tumors. 2. utg. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2006.
  46. Berquist TH, Ehman RL, King BF, Hodgman CG, Ilstrup DM. Value of MR imaging in differentiating benign from malignant soft-tissue masses: study of 95 lesions. AJR Am J Roentgenol 1990;155(6):1251–5.
  47. Moulton JS, Blebea JS, Dunco DM, Braley SE, Bisset GS, III, Emery KH. MR imaging of soft-tissue masses: diagnostic efficacy and value of distinguishing between benign and malignant lesions. AJR Am J Roentgenol 1995;164(5):1191–9.
  48. Grimer RJ, Carter SR, Tillman RM, Abudu A. Early symptoms and diagnosis of bone tumors. J Bone Joint Surg Am 2001;83-A(7):1107–8.
  49. Grimer RJ, Sneath RS. Diagnosing malignant bone tumours. J Bone Joint Surg Br 1990;72(5):754–6.
  50. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000;82(5):667–74.
  51. Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res 2016;6:7.
  52. Miller TT. Bone tumors and tumorlike conditions: analysis with conventional radiography. Radiology 2008;246(3):662–74.
  53. Moser RP, Jr., Madewell JE. An approach to primary bone tumors. Radiol Clin North Am 1987;25(6):1049–93.
  54. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am 1982;64(8):1121–7.
  55. Dyrop HB, Vedsted P, Safwat A, Maretty-Nielsen K, Hansen BH, Jørgensen PH, et al. Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center. Acta Orthop 2014;85(6):657–62.
  56. Salunke AA, Chen Y, Tan JH, Chen X, Khin LW, Puhaindran ME. Does a pathological fracture affect the prognosis in patients with osteosarcoma of the extremities? : a systematic review and meta-analysis. Bone Joint J 2014;96-B(10):1396–403.
  57. Gielen JL, De Schepper AM, Vanhoenacker F, Parizel PM, Wang XL, Sciot R, et al. Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. Eur Radiol 2004;14(12):2320–30.
  58. Ma LD, McCarthy EF, Bluemke DA, Frassica FJ. Differentiation of benign from malignant musculoskeletal lesions using MR imaging: pitfalls in MR evaluation of lesions with a cystic appearance. AJR Am J Roentgenol 1998;170(5):1251–8.
  59. Weatherall PT. Benign and malignant masses. MR imaging differentiation. Magn Reson Imaging Clin N Am 1995;3(4):669–94.
  60. Petasnick JP, Turner DA, Charters JR, Gitelis S, Zacharias CE. Soft-tissue masses of the locomotor system: comparison of MR imaging with CT. Radiology 1986;160(1):125–33.
  61. Coates M. Ultrasound and soft-tissue mass lesions--a note of caution. N Z Med J 2003;116(1187):U706.
  62. Beggs I. Ultrasound of soft tissue masses. Imaging 2002;14(3):202–8.
  63. Alyas F, James SL, Davies AM, Saifuddin A. The role of MR imaging in the diagnostic characterisation of appendicular bone tumours and tumour-like conditions. Eur Radiol 2007;17(10):2675–86.
  64. Kransdorf MJ. Society of skeletal radiology 2008 annual meeting. Skeletal Radiol 2009;38(1):97–100.
  65. Aisen AM, Martel W, Braunstein EM, McMillin KI, Phillips WA, Kling TF. MRI and CT evaluation of primary bone and soft-tissue tumors. AJR Am J Roentgenol 1986;146(4):749–56.
  66. Tehranzadeh J, Mnaymneh W, Ghavam C, Morillo G, Murphy BJ. Comparison of CT and MR imaging in musculoskeletal neoplasms. J Comput Assist Tomogr 1989;13(3):466–72.
  67. Becher S, Oskouei S. PET Imaging in Sarcoma. Orthop Clin North Am 2015;46(3):409–15, xi.
  68. Kubo T, Furuta T, Johan MP, Ochi M. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis. Eur J Cancer 2016;58:104–11.
  69. Li YJ, Dai YL, Cheng YS, Zhang WB, Tu CQ. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis. Eur J Surg Oncol 2016;42(8):1103–14.
  70. Chen L, Wu X, Ma X, Guo L, Zhu C, Li Q. Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis. Medicine 2017;96(6):e5913.
  71. Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, et al. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging 2017;44(2):215–23.
  72. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007;245(3):839–47.
  73. Roberge D, Vakilian S, Alabed YZ, Turcotte RE, Freeman CR, Hickeson M. FDG PET/CT in Initial Staging of Adult Soft-Tissue Sarcoma. Sarcoma 2012;2012: 960194.
  74. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU, 3rd, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103(2):339–48.
  75. Quak E, van de Luijtgaarden AC, de Geus-Oei LF, van der Graaf WT, Oyen WJ. Clinical applications of positron emission tomography in sarcoma management. Expert Rev Anticancer Ther 2011;11(2):195–204.
  76. Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25(34):5435–41.
  77. Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, et al. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer 2013;119(6):1227–34.
  78. Eary JF, Conrad EU. Imaging in sarcoma. J Nucl Med 2011;52(12):1903–13.
  79. Quartuccio N, Fox J, Kuk D, Wexler LH, Baldari S, Cistaro A, et al. Pediatric bone sarcoma: diagnostic performance of (1)(8)F-FDG PET/CT versus conventional imaging for initial staging and follow-up. AJR Am J Roentgenol 2015;204(1):153–60.
  80. Garner HW, Kransdorf MJ, Peterson JJ. Posttherapy imaging of musculoskeletal neoplasms. Radiol Clin North Am 2011;49(6):1307–23, vii.
  81. Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 2012;14(2):252–9.
  82. Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V, et al. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med 2013;54(2):176–83.
  83. Mosci C, Iagaru A. (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET Clin 2012;7(3):263–74.
  84. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15(8):2856–63.
  85. Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, et al. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma 2010;2010: 143540.
  86. Meyer JS, Nadel HR, Marina N, Womer RB, Brown KL, Eary JF, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008;51(2):163–70.
  87. Kaste SC. Imaging pediatric bone sarcomas. Radiol Clin North Am 2011;49(4):749–65, vi-vii.
  88. Fuglø HM, Jørgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of (1)(8)F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging 2012;39(9):1416–24.
  89. Iagaru A, Mosci C, Dick DW, Sathekge M, Lapa P, de Lima JM, et al. Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies. Eur J Nucl Med Mol Imaging 2013;40(12):1922–4.
  90. Jackson T, Mosci C, von Eyben R, Mittra E, Ganjoo K, Biswal S, et al. Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients. Clin Nucl Med 2015;40(9):720–4.
  91. Esmo European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii100–9.
  92. Fletcher CDM, Krishnan Unni K, Mertens F, red. Pathology and genetics of tumours of soft tissue and bone. 4. utg. Lyon: IARC Press; 2002. World Health Organization classification of tumours.
  93. Weiss SW, Enzinger FM, Goldblum JR. Enzinger and Weiss’s soft tissue tumors. 5. utg. Philadelphia: Mosby Elsevier; 2008.
  94. Broders AC. Squamous-cell epithelioma of the lip: a study of five hundred and thirty-seven cases. J Am Med Assoc 1920;74(10):656–64.
  95. Broders AC, Hargrave R, Meyerding HW. Pathological features of soft tissue fibrosarcoma with special reference to the grading of its malignancy. Surg Gynecol Obstet 1939;69:267–80.
  96. Angervall L, Kindblom LG. Principles for pathologic-anatomic diagnosis and classification of soft-tissue sarcomas. Clin Orthop Relat Res 1993;(289):9–18.
  97. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130(10):1466–78.
  98. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002;10(2):81–9.
  99. Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13(3):265–74.
  100. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002;94(9):2511–6.
  101. College of American Pathologists [nettside]. Northfield, IL: CAP [oppdatert 2012; lest 2012]. Tilgjengelig fra: www.cap.org
  102. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;(153):106–20.
  103. Davis AM, O’Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005;75(1):48–53.
  104. Gerrand CH, Bell RS, Wunder JS, Kandel RA, O’Sullivan B, Catton CN, et al. The influence of anatomic location on outcome in patients with soft tissue sarcoma of the extremity. Cancer 2003;97(2):485–92.
  105. O’Sullivan B, Wylie J, Catton C, Gutierrez E, Swallow CJ, Wunder J, et al. The local management of soft tissue sarcoma. Semin Radiat Oncol 1999;9(4):328–48.
  106. le Grange F, Cassoni AM, Seddon BM. Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma. Eur J Surg Oncol 2014;40(4):394–401.
  107. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4(7):429–37.
  108. Smith HG, Cartwright J, Wilkinson MJ, Strauss DC, Thomas JM, Hayes AJ. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor alpha for In-Transit Melanoma and Soft Tissue Sarcoma. Ann Surg Oncol 2015;22 Suppl 3:S356–61.
  109. Gerbers JG, Stevens M, Ploegmakers JJ, Bulstra SK, Jutte PC. Computer-assisted surgery in orthopedic oncology. Acta Orthop 2014;85(6):663–9.
  110. Igarashi K, Yamamoto N, Shirai T, Hayashi K, Nishida H, Kimura H, et al. The long-term outcome following the use of frozen autograft treated with liquid nitrogen in the management of bone and soft-tissue sarcomas. Bone Joint J 2014;96-B(4):555–61.
  111. Higuchi T, Yamamoto N, Nishida H, Hayashi K, Takeuchi A, Kimura H, et al. Knee joint preservation surgery in osteosarcoma using tumour-bearing bone treated with liquid nitrogen. Int Orthop 2017;Jun 1 [Epub ahead of print].
  112. Wafa H, Grimer RJ, Reddy K, Jeys L, Abudu A, Carter SR, et al. Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients: case-control study. Bone Joint J 2015;97-B(2):252–7.
  113. Schmidt-Braekling T, Streitbuerger A, Gosheger G, Boettner F, Nottrott M, Ahrens H, et al. Silver-coated megaprostheses: review of the literature. Eur J Orthop Surg Traumatol 2017;27(4):483–9.
  114. Hardes J, von Eiff C, Streitbuerger A, Balke M, Budny T, Henrichs MP, et al. Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol 2010;101(5):389–95.
  115. Pisters PWT. Retroperitoneal sarcomas. I: Pollock RE, red. Soft tissue sarcomas. Hamilton: Decker; 2002. s. 180–8.
  116. Weiss SW, Goldblum JR. Sarcomas in the retroperitoneum. I: Weiss SW, red. Enzinger and Weiss’s soft tissue tumors. St. Louis: Mosby; 2001. s. 37–44.
  117. Stoldt HS, Geraghty JG. Surgical principles in the management of soft tissue sarcomas. I: Taylor I, Johnson CD, red. Recent advances in surgery. London: Royal Society of Medicine Press; 1999. s. 47–61.
  118. Sæter G, Helgerud P, Talle K. Retroperitonal soft tissue sarcoma. The Norwegian Radium hospital (NRH) experience. Presentasjon på SSG 20th anniversary meeting; Oslo 1999.
  119. Nussbaum DP, Rushing CN, Lane WO, Cardona DM, Kirsch DG, Peterson BL, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol 2016;17(7):966–75.
  120. Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 1997;15(8):2832–9.
  121. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228(3):355–65.
  122. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001;92(2):359–68.
  123. Karakousis CP, Velez AF, Gerstenbluth R, Driscoll DL. Resectability and survival in retroperitoneal sarcomas. Ann Surg Oncol 1996;3(2):150–8.
  124. Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer 2004;100(11):2448–55.
  125. Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990;212(1):51–9.
  126. Canter RJ, Qin LX, Ferrone CR, Maki RG, Singer S, Brennan MF. Why do patients with low-grade soft tissue sarcoma die? Ann Surg Oncol 2008;15(12):3550–60.
  127. Shibata D, Lewis JJ, Leung DH, Brennan MF. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? J Am Coll Surg 2001;193(4):373–9.
  128. Recommendations for the diagnosis and treatment of intraabdominal, retroperitoneal and uterine sarcoma (SSG XVII Version 2). Lund: Scandinavian Sarcoma Group and Oncologic Center; 2008. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/SSGXVII-Version2_2008.doc.pdf
  129. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001;8(4):290–9.
  130. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231(1):51–8.
  131. Chaudhry UI, DeMatteo RP. Management of resectable gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009;23(1):79–96.
  132. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33(5):466–77.
  133. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99(1):42–7.
  134. Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, et al. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol 2014;21(8):2499–505.
  135. Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, et al. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol 2013;39(2):150–5.
  136. Al-Absi E, Farrokhyar F, Sharma R, Whelan K, Corbett T, Patel M, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol 2010;17(5):1367–74.
  137. O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325):2235–41.
  138. Pisters PW, O’Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007;25(8):1003–8.
  139. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16(1):197–203.
  140. Trovik CS, Bauer HC, Berlin O, Tukiainen E, Erlanson M, Gustafson P, et al. Local recurrence of deep-seated, high-grade, soft tissue sarcoma: 459 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand 2001;72(2):160–6.
  141. Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005;63(3):852–9.
  142. Wang D, Bosch W, Roberge D, Finkelstein SE, Petersen I, Haddock M, et al. RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies. Int J Radiat Oncol Biol Phys 2011;81(4):e525–8.
  143. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233(1):93–100.
  144. Haas RL, Delaney TF, O’Sullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys 2012;84(3):572–80.
  145. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21(1):109–22.
  146. Milano MT, Constine LS, Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 2007;17(2):131–40.
  147. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10–9.
  148. Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol 2008;26(20):3440–4.
  149. Levernes S, Johannessen DC. Volum og doser ved strålebehandling: definisjoner, retningslinjer for bruk, dokumentasjon og rapportering. Østerås: Statens Strålevern; 2003. StrålevernRapport 2003: 12. Tilgjengelig fra: http://www.nrpa.no/dav/a1de986ad7.pdf
  150. Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE. The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009;10(1–2):94–106.
  151. Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Tihan T, et al. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol 2010;98(1):101–8.
  152. Demizu Y, Jin D, Sulaiman NS, Nagano F, Terashima K, Tokumaru S, et al. Particle Therapy Using Protons or Carbon Ions for Unresectable or Incompletely Resected Bone and Soft Tissue Sarcomas of the Pelvis. Int J Radiat Oncol Biol Phys 2017;98(2):367–74.
  153. Uhl M, Edler L, Jensen AD, Habl G, Oelmann J, Röder F, et al. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol. Radiat Oncol 2014;9:100.
  154. Jebsen NL, Bruland ØS, Eriksson M, Engellau J, Turesson I, Folin A, et al. Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. Int J Radiat Oncol Biol Phys 2011;81(5):1359–66.
  155. Jebsen NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, et al. Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study. Int J Radiat Oncol Biol Phys 2008;71(4):1196–203.
  156. Alektiar KM, Velasco J, Zelefsky MJ, Woodruff JM, Lewis JJ, Brennan MF. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 2000;48(4):1051–8.
  157. Wolfson AH, Benedetto PW, Mnaymneh W, Moffat FL, Robinson DS, Boyer C, et al. Does a radiation dose-response relation exist concerning survival of patients who have soft-tissue sarcomas of the extremities? Radiation dose-response relation for soft-tissue sarcomas. Am J Clin Oncol 1998;21(3):270–4.
  158. Zagars GK, Ballo MT. Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys 2003;56(2):473–81.
  159. Fein DA, Lee WR, Lanciano RM, Corn BW, Herbert SH, Hanlon AL, et al. Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy interval impact on local control? Int J Radiat Oncol Biol Phys 1995;32(4):969–76.
  160. Trovik LH, Ovrebo K, Almquist M, Haugland HK, Rissler P, Eide J, et al. Adjuvant radiotherapy in retroperitoneal sarcomas. A Scandinavian Sarcoma Group study of 97 patients. Acta Oncol 2014;53(9):1165–72.
  161. Koontz BF, Clough RW, Halperin EC. Palliative radiation therapy for metastatic Ewing sarcoma. Cancer 2006;106(8):1790–3.
  162. Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, et al. An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol 2012;103(1):8–11.
  163. Noel G, Habrand JL, Jauffret E, de Crevoisier R, Dederke S, Mammar H, et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 2003;179(4):241–8.
  164. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002;54(3):824–9.
  165. Suit H, Kooy H, Trofimov A, Farr J, Munzenrider J, DeLaney T, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 2008;86(2):148–53.
  166. Igaki H, Tokuuye K, Okumura T, Sugahara S, Kagei K, Hata M, et al. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 2004;60(4):1120–6.
  167. Noel G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Haie-Meder C, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 2005;44(7):700–8.
  168. Habrand JL, Schneider R, Alapetite C, Feuvret L, Petras S, Datchary J, et al. Proton therapy in pediatric skull base and cervical canal low-grade bone malignancies. Int J Radiat Oncol Biol Phys 2008;71(3):672–5.
  169. Rosenberg AE, Nielsen GP, Keel SB, Renard LG, Fitzek MM, Munzenrider JE, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 1999;23(11):1370–8.
  170. Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011;117(19):4522–30.
  171. Rombi B, DeLaney TF, MacDonald SM, Huang MS, Ebb DH, Liebsch NJ, et al. Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 2012;82(3):1142–8.
  172. Hug EB, Adams J, Fitzek M, De Vries A, Munzenrider JE. Fractionated, three-dimensional, planning-assisted proton-radiation therapy for orbital rhabdomyosarcoma: a novel technique. Int J Radiat Oncol Biol Phys 2000;47(4):979–84.
  173. Lee CT, Bilton SD, Famiglietti RM, Riley BA, Mahajan A, Chang EL, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005;63(2):362–72.
  174. Swanson EL, Indelicato DJ, Louis D, Flampouri S, Li Z, Morris CG, et al. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. Int J Radiat Oncol Biol Phys 2012;83(5):1549–57.
  175. Weber DC, Trofimov AV, Delaney TF, Bortfeld T. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys 2004;58(5):1596–606.
  176. Jingu K, Tsujii H, Mizoe JE, Hasegawa A, Bessho H, Takagi R, et al. Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;82(5):2125–31.
  177. Kamada T, Tsujii H, Tsuji H, Yanagi T, Mizoe JE, Miyamoto T, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 2002;20(22):4466–71.
  178. Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010;11(6):561–70.
  179. Issels R, Lindner LH. Regional hyperthermia for high-risk soft tissue sarcoma treatment: present status and next questions. Curr Opin Oncol 2016;28(5):447–52.
  180. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113(3):573–81.
  181. Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13(10):1045–54.
  182. A scandinavian sarcoma group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall (SSG XX). Lund: Scandinavian Sarcoma Group, Oncologic Center; 2007. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/SSG%20XX%20June%202007.pdf
  183. An italian – scandinavian treatment protocol for nonmetastatic Ewing’s family tumors (ISG/SSG III). Bologna; Lund: Italian sarcoma group (ISG), Scandinavian sarcoma group and oncologic center (SSG); 1999. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/ISGSSG3-1999.pdf
  184. Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39(4):488–94.
  185. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23(34):8845–52.
  186. Euramos 1. Randomised trial of the European and American osteosarcoma study group to optimise treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. European and American Osteosarcoma Study Group; 2012. Tilgjengelig fra: http://www.ctu.mrc.ac.uk/euramos/euramos_i_trial.asp
  187. Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 2016;17(10):1396–408.
  188. Strander H, Bauer HC, Brosjö O, Fernberg JO, Kreicbergs A, Nilsonne U, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995;34(6):877–80.
  189. Strander H, Einhorn S. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 1977;19(4):468–73.
  190. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 2015;33(20):2279–87.
  191. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children’s Oncology Group. J Clin Oncol 2008;26(4):633–8.
  192. Scandinavian Sarcoma Group, Oncologic Center Lund. Euroboss I. A European treatment protocol for bone sarcoma in patients older than 40 years. Lund: Scandinavian Sarcoma Group; 2003. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/Euroboss1.pdf
  193. Paulussen M, Bielack S, Jurgens H, Casali PG, Esmo Guidelines Working Group. Ewing’s sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:140–2.
  194. Ferrari S, Alvegard T, Luksch R, Tienghi A, Hall KS, Bernini G, et al. Non-metastatic Ewing’s family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Preliminary results of the Italian/Scandinavian ISG/SSG III protocol. J Clin Oncol (2007 ASCO Aannual Meeting Proceedings) 2007;25(18S):abs no 10014.
  195. Whelan J, Le Deley M-C, Dirksen U, Judson IR, Hawkins DS, Van Den Berg H, et al. Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc). J Clin Oncol 2016;34(15 suppl):11000.
  196. Luksch R, Tienghi A, Hall KS, Fagioli F, Picci P, Barbieri E, et al. Primary metastatic Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol 2012;23(11):2970–6.
  197. The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii102-iii12.
  198. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii21-iii6.
  199. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26(4):620–5.
  200. Hompland I, Bruland OS, Holmebakk T, Poulsen JP, Stoldt S, Hall KS, et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncol 2017;May 30 [Epub ahead of print].
  201. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127–34.
  202. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41(12):1751–7.
  203. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307(12):1265–72.
  204. Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol 2016;34(3):244–50.
  205. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39(10):1411–9.
  206. Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 2012;9(6):351–8.
  207. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 2009;35(7):739–45.
  208. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329–38.
  209. Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer 2016;16:22.
  210. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370(9604):2011–9.
  211. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009;7(1):11–9.
  212. Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016;17(5):632–41.
  213. Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol 2014;6(5):222–8.
  214. Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study. Radiother Oncol 2015;116(2):233–8.
  215. Garcia del Muro X. Nilotinib, imatinib, and GIST therapy. Lancet Oncol 2015;16(5):483–4.
  216. Goodman KA, Kavanagh BD. Stereotactic Body Radiotherapy for Liver Metastases. Semin Radiat Oncol 2017;27(3):240–6.
  217. Childhood cancer in the nordic countries. Report from NOPHO annual meeting in Lindköping. Lindköping: Nordic society of pediatric haematology and oncology (NOPHO); 2008.
  218. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21(10):2011–8.
  219. Paulussen M, Kovar H, Jürgens H. Ewing sarcoma and peripheral primitive neuroectodermal tumour. I: Voûte PA, Barrett A, Stevens MCG, red. Cancer in children: clinical management. Oxford: Oxford universtity press; 2005. s. 301–20.
  220. Bisogno G, Bergeron C. Soft tissue sarcoma. I: Voûte PA, Barrett A, Stevens MCG, red. Cancer in children: clinical management. Oxford: Oxford university press; 2005. s. 255–79.
  221. An italian – scandinavian treatment protocol for high-risk Ewing’s family tumors (ISG/SSG IV). Bologna; Lund: Italian sarcoma group (ISG), Scandinavian sarcoma group and oncologic center (SSG); 1999. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/ISGSSGIV-1999.pdf
  222. EpSSG RMS 2005: a protocol for non metastatic rhabdomyosarcoma [nettdokument]. Padua, Italy: European paediatric soft tissue sarcoma study group [oppdatert 2005; lest mai 2012]. Tilgjengelig fra: http://epssg.cineca.org/clinical_trials.htm
  223. EpSSG NRSTS 2005: a protocol for localised non rhabdomyosarcoma soft tissue sarcomas [nettdokument]. Padua, Italy: European paediatric soft tissue sarcoma study group [oppdatert 2005; lest mai 2012]. Tilgjengelig fra: http://epssg.cineca.org/clinical_trials.htm
  224. Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol 2011;22(5):1221–7.
  225. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54(3):355–64.
  226. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55(5):321–5.
  227. Nordal RR. Uterine sarcomas in Norway 1956–1992: an epidemiological and clinicopathological study [doktorgrad]. Oslo: Faculty of Medicine, University of Oslo; 1998.
  228. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83(3):414–8.
  229. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 2016;34(8):786–93.
  230. Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012;124(1):48–52.
  231. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879–86.
  232. Dahhan T, Fons G, Buist MR, Ten Kate FJ, van der Velden J. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol 2009;144(1):80–4.
  233. Nakayama K, Ishikawa M, Nagai Y, Yaegashi N, Aoki Y, Miyazaki K. Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate. Int J Clin Oncol 2010;15(2):179–83.
  234. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft. 4. utg. Oslo: Helsedirektoratet; 2007. IS-2201. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-pasienter-med-brystkreft
  235. Tangvik RJ, Tell GS, Guttormsen AB, Eisman JA, Henriksen A, Nilsen RM, et al. Nutritional risk profile in a university hospital population. Clin Nutr 2015;34(4):705–11.
  236. Nasjonale faglige retningslinjer for forebygging og behandling av underernæring. Oslo: Helsedirektoratet; 2009. IS-1580. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonal-faglig-retningslinje-for-forebygging-og-behandling-av-underernering/Publikasjoner/nasjonal-faglig-retningslinje-for-forebygging-og-behandling-av-underernering.PDF
  237. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36(1):11–48.
  238. Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS()) Society recommendations. World J Surg 2013;37(2):259–84.
  239. Giraudet-Le Quintrec JS, Coste J, Vastel L, Pacault V, Jeanne L, Lamas JP, et al. Positive effect of patient education for hip surgery: a randomized trial. Clin Orthop Relat Res 2003;(414):112–20.
  240. Prasad SA, Pryor JA, red. Physiotherapy for respiratory and cardiac problems: adults and paediatrics. Edinburgh: Churchill Livingstone Elsevier; 2008.
  241. Hough A. Physiotherapy in respiratory care: an evidence-based approach to respiratory and cardiac management. Cheltenham: Trans-Atlantic Publications; 2001.
  242. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23(10):2123–9.
  243. Elvsaas I-KØ, Graff BA, Harboe I, Norderhaug IN. Kompresjonsstrømper i forebygging av dyp venetrombose. Oslo: Nasjonalt kunnskapsenter for helsetjenesten; 2008. Rapport fra Kunnskapssenteret nr. 28. Tilgjengelig fra: https://www.fhi.no/publ/eldre/kompresjonsstromper-i-forebygging-av-dyp-venetrombose-/
  244. Markhede G, Stener B. Function after removal of various hip and thigh muscles for extirpation of tumors. Acta Orthop Scand 1981;52(4):373–95.
  245. Aksnes LH. Health in long-term survivors of bone sarcoma [Doktorgrad]. Oslo: Faculty of Medicine, University of Oslo Unipub; 2008.
  246. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008;(2):CD006145.
  247. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne lymfomer. rev utg. Oslo: Helsedirektoratet; 2012. IS-1594. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-maligne-lymfomer/Sider/default.aspx
  248. Jordhøy MS, Fayers P, Loge JH, Ahlner-Elmqvist M, Kaasa S. Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Oncol 2001;19(18):3884–94.
  249. Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. rev utg. Oslo: Helsedirektoratet; 2013. IS-2101. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen-/Sider/default.aspx
  250. Esmo European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii92–9.
  251. E. SMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii21–6.
  252. Esmo European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii49–55.
  253. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY, Group EGW. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:132–6.
  254. Scandinavian Sarcoma Group, Oncologic Center Lund. Recommendations for treatment of metastatic soft-tissue sarcomas in adult patients (SSG XIX). Lund: Scandinavian Sarcoma Group; 2004. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/SSG%20XIX.pdf
  255. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000;18(10):2081–6.
  256. Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol 2010;21 Suppl 7:vii270–6.
  257. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26(32):5269–74.
  258. Le Cesne A, Blay JY, Judson I, Van OA, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23(3):576–84.
  259. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20(8):1439–44.
  260. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20(12):2824–31.
  261. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017;Sep 4 [Epub ahead of print].
  262. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27(19):3126–32.
  263. Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999;10(5):453–6.
  264. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016;388(10043):488–97.
  265. Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387(10028):1629–37.
  266. Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, et al. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol 2017;Aug 30 [Epub ahead of print].
  267. Bielack SS, Carrle D. State-of-the-art approach in selective curable tumors: bone sarcoma. Ann Oncol 2008;19 Suppl 7:vii155-vii60.
  268. An italian – scandinavian treatment protocol for metastatic and pelvic osteosarcoma (ISG/SSG II). Bologna; Lund: Italian sarcoma group (ISG), Scandinavian sarcoma group and oncologic center (SSG); 2002.
  269. Boye K, Del Prever AB, Eriksson M, Saeter G, Tienghi A, Lindholm P, et al. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study. Pediatr Blood Cancer 2014;61(5):840–5.
  270. Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, et al. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer 2016;16:280.
  271. Kung FH, Pratt CB, Vega RA, Jaffe N, Strother D, Schwenn M, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993;71(5):1898–903.
  272. Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 2005;44(4):338–47.
  273. Safwat A, Boysen A, Lücke A, Rossen P. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol 2014;53(10):1451–4.
  274. Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartementet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf